您的位置: 首页 > 2017年11月 第48卷 第6期 > 文字全文
2023年7月 第38卷 第7期11
目录

二甲双胍和胰高糖素样多肽-1对2型糖尿病患者并发骨折恢复的影响

Effects of metformin and glucagon like polypeptide -1 on fracture recovery in patients with type 2 diabetes mellitus

来源期刊: 广州医药 | 33-35 发布时间:2021-12-01 收稿时间:2025/11/13 17:07:55 阅读量:34
作者:
关键词:
低剂量高剂量二甲双胍胰高糖素样多肽-1骨折愈合
Low doseHigh doseMetforminGlucagon like polypeptide -1Fracture recovery
DOI:
10.3969/j.issn.1000-8535.2017.06.010
收稿时间:
2017-06-26 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 探讨二甲双胍和胰高糖素样多肽-1对2型糖尿病患者并发骨折恢复的影响。方法 选取2016年5月—2017年4月我院骨科收治的2型糖尿病并发骨折患者120例,按随机原则分为5组,每组24例,单药低剂量二甲双胍组(A1)、单药高剂量二甲双胍组(A2)、单药GLP-1组(B)、低剂量二甲双胍联合GLP-1组(C1)和高剂量二甲双胍联合GLP-1组(C2)。二甲双胍低剂量用药量为0.5 g/次,每日2次口服,高剂量用药量为0.5 g/次,每日4次口服。皮下注射利拉鲁肽每日1次,起始量为每日0.6 mg,1周增加为每日1.2 mg,再1周后增加为每日1.8 mg。血糖控制在理想水平后按照标准的手术方法和规程行相应的手术治疗。同时给予饮食控制及其它对症治疗。分别在1、3、6个月时检测其股骨颈骨密度值(BMD)和Harris系统评分。结果 随着治疗时间延长,A1组、C1组、C2组BMD值和Harris系统评分均增高, 在术后3月和6月时,C1组骨密度值和Harris评分高于A1组(P<0.05), C1组骨密度值和Harris评分高于C2组(P<0.05)。结论 胰高糖素样多肽-1可促进2型糖尿病患者骨折愈合、功能恢复,且与低剂量二甲双胍联用促进骨折愈合效果优于与高剂量二甲双胍联用。
Objective To investigate the effects of metformin and glucagon like polypeptide -1 on fracture recovery in patients with type 2 diabetes mellitus(DM). Methods We selected 120 patients with type 2 diabetes mellitus from May 2016 to April 2017 in department of orthopedicsin in our hospital and randomly divided them into 5 groups, 24 cases in each group,includingthe low dose of metformin monotherapy group (A1), the high dose of metformin monotherapy group (A2), single drug GLP-1 group (B), and GLP-1 group low dose of metformin combination (C1) and high dose of metformin combination with GLP-1 group (C2). The low dose of metformin was 0.5 g / time, 2 times a day for oral administration. The high dose was 0.5 g / time, 4 times a day. Subcutaneous injection of liraglutide was once daily, starting at a daily dose of 0.6 mg, 1.2 mg daily after 1 week and 1.8 mg daily after another week. After an ideal level of blood glucose control, corresponding surgical procedures should be performed according to standard surgical methods and procedures. Diet control and other symptomatic treatments were also given. The femoral neck bone mineral density (BMD) and the Harris system score were examined at the first, third, and sixth month respectively. Results With the prolongation of treatment time, the BMD value and Harris system score in the A1 group, C1 group, C2 group were increased. After surgery in March and June, the BMD and Harris score of C1 group were higher than that of A1 group (P<0.05). The bone mineral density and Harris score of C1 group was significantly higher than that of group C2 (P<0.05). Conclusion Glucagon like peptide -1 may promote the fracture recovery and functional recovery in patients with type 2 diabetes mellitus, and with combination of low dose metformin is more effective than that with high dose metformin.
1、 刘玥明,闻杰. 胰高血糖素样肽-1受体激动剂的研究进展[J]. 世界临床药物, 2016, 37(12): 814-817. 刘玥明,闻杰. 胰高血糖素样肽-1受体激动剂的研究进展[J]. 世界临床药物, 2016, 37(12): 814-817.
2、 刘冬梅,刘建民. 二甲双胍对骨代谢的影响[J]. 中华骨质疏松和骨矿盐疾病杂志, 2010, 3(2): 133-135. 刘冬梅,刘建民. 二甲双胍对骨代谢的影响[J]. 中华骨质疏松和骨矿盐疾病杂志, 2010, 3(2): 133-135.
3、 黄春仁, 洪文婕, 何君华. 不同剂量二甲双胍用于2型糖尿病性骨质疏松症伴股骨颈骨折患者中的临床效果[J]. 中国现代药物应用, 2017, 11(3): 9-11. 黄春仁, 洪文婕, 何君华. 不同剂量二甲双胍用于2型糖尿病性骨质疏松症伴股骨颈骨折患者中的临床效果[J]. 中国现代药物应用, 2017, 11(3): 9-11.
4、 魏开惠, 王振华. 二甲双胍对2型糖尿病患者骨代谢的影响[J]. 实用临床医药杂志, 2015, 19(13): 117-118. 魏开惠, 王振华. 二甲双胍对2型糖尿病患者骨代谢的影响[J]. 实用临床医药杂志, 2015, 19(13): 117-118.
5、 王春雷, 朱紫薇, 金晖. GLP-1对GK糖尿病大鼠骨髓间充质干细胞骨向分化能力的影响[J]. 中国骨质疏松杂志, 2015, 21(3): 298-303. 王春雷, 朱紫薇, 金晖. GLP-1对GK糖尿病大鼠骨髓间充质干细胞骨向分化能力的影响[J]. 中国骨质疏松杂志, 2015, 21(3): 298-303.
6、 左贵来. 糖尿病对大鼠骨折愈合的影响和GLP-1干预治疗的实验研究[D]. 泰安:泰山医学院, 2011. 左贵来. 糖尿病对大鼠骨折愈合的影响和GLP-1干预治疗的实验研究[D]. 泰安:泰山医学院, 2011.
7、 许晓娜, 乔虹. 胰高血糖素样多肽-1在2型糖尿病治疗中的新进展[J]. 东南大学学报(医学版), 2017, 36(2): 270-274. 许晓娜, 乔虹. 胰高血糖素样多肽-1在2型糖尿病治疗中的新进展[J]. 东南大学学报(医学版), 2017, 36(2): 270-274.
8、 罗阳燕, 卫怡勋, 毛楠, 等. 胰高血糖素样肽-1胰腺外作用研究进展[J]. 保健医学研究与实践, 2016, 13(6): 78-80. 罗阳燕, 卫怡勋, 毛楠, 等. 胰高血糖素样肽-1胰腺外作用研究进展[J]. 保健医学研究与实践, 2016, 13(6): 78-80.
9、 GUO X H, YUAN L, LOU Q Q, et al. A nationwide survey of diabetes education, self-management and glycem ic control in patients with type 2 diabetes in China[J]. Chin Med J, 2012, 125(23): 4175-4180. GUO X H, YUAN L, LOU Q Q, et al. A nationwide survey of diabetes education, self-management and glycem ic control in patients with type 2 diabetes in China[J]. Chin Med J, 2012, 125(23): 4175-4180.
10、 CHAN J C N, ZHANG Y, NING G. Diabetes in China: a societal solution for a personal challenge[J]. Lancet Diabetes Endocrinol, 2014, 2(12): 969-979. CHAN J C N, ZHANG Y, NING G. Diabetes in China: a societal solution for a personal challenge[J]. Lancet Diabetes Endocrinol, 2014, 2(12): 969-979.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录